MeiraGTx's innovative gene therapies for ocular diseases & more are backed by strong clinical data and funding. Click here to find out why MGTX stock is a Buy.
Oxford, UK - 21 March 2025: OXB (LSE: OXB) (the "Company"), a quality and innovation-led cell and gene therapy CDMO, today ...
The first-of-its-kind facility in India has received an investment of $75 million from the company to build it vertically ...
4h
DelveInsight's "LUXTURNA Market Size, Forecast, and Market Insight Report" highlights the details around LUXTURNA, a one-time ...
The Adeno Associated Virus Vector Manufacturing market, valued at USD 1,148.4 million in 2024, is expected to register robust revenue CAGR of 19.6%.Request free copy of this report: March 14, 2025 - ...
LUXTURNA has significant market potential due to the high unmet need for effective treatments in rare genetic conditions. With its FDA approval for specific mutations in the RPE65 gene, it offers ...
First and only immunotherapy to show meaningful overall survival benefit in a Phase 2 trial in patients with advanced ovarian cancer. Initiation of trial sites underway for ground ...
First and only immunotherapy to show meaningful overall survival benefit in a Phase 2 trial in patients with advanced ovarian cancer Initiation of trial sites underway for ground-breaking Phase 3 pivo ...
Genetic engineering in non-human primates has long been limited by the need for virus-based gene delivery methods. Recently, ...
Edinburgh-based biotech company Lentitek Ltd has secured £700,000 in private funding from Equity Gap, a leading Scottish angel investment syndicate, bringing its total investment to £1 million in the ...
Genetic engineering in non-human primates has long been limited by the need for virus-based gene delivery methods. Recently, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback